Prognostic and predictive value of Phospho-p44/42 and pAKT in HER2-positive locally advanced breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy.

found that Phospho-p44/42 and pAKT were not associated with the clinical outcome, although low Phospho-p44/42 expression showed a trend for association with a longer overall survival [ 18 ].

also in 53,322 other papers

Patients with high post-Phospho-p44/42 expression had a higher recurrence rate (up to 68%) in the first 5 years, while patients with low post-Phospho-p44/42 expression had a lower recurrence rate (45%), and the survival difference between the two groups was highly significant.

also in 132,142 other papers